{"id":"tritanrix-hepb-hib-menac","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, or swelling at the injection site"}]},"_chembl":{"chemblId":"CHEMBL2108875","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by stimulating the body's immune system to produce antibodies against these pathogens, providing immunity against future infections.","oneSentence":"Tritanrix-HepB/Hib-MenAC is a vaccine that protects against diphtheria, tetanus, hepatitis B, and meningococcal and Haemophilus influenzae type b diseases.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:07.845Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Protection against diphtheria, tetanus, hepatitis B, and meningococcal and Haemophilus influenzae type b diseases"}]},"trialDetails":[{"nctId":"NCT00136604","phase":"PHASE3","title":"Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01-22","conditions":"Whole Cell Pertussis, Haemophilus Influenzae Type b, Hepatitis B","enrollment":617},{"nctId":"NCT00228917","phase":"PHASE3","title":"Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-06-16","conditions":"Whole Cell Pertussis, Tetanus, Hepatitis B","enrollment":798},{"nctId":"NCT00317135","phase":"PHASE3","title":"Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 & 6 Months Age) After a Birth Dose of Hepatitis B.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-12-11","conditions":"Diphtheria, Hepatitis B, Whole Cell Pertussis","enrollment":500},{"nctId":"NCT00317187","phase":"PHASE3","title":"Safety Study of a Vaccine Against Meningitis in Infants (2,4 & 6 Months Age) After a Birth Dose of Hepatitis B.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-06-08","conditions":"Hepatitis B, Diphtheria, Whole Cell Pertussis","enrollment":500},{"nctId":"NCT00291343","phase":"PHASE3","title":"Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-02-01","conditions":"Infections, Meningococcal","enrollment":296},{"nctId":"NCT00197275","phase":"PHASE3","title":"Lot-to-lot Consistency of Tritanrix™-HepB/Hib-MenAC & Its Non-inferiority vs Tritanrix™-HepB/Hiberix™ in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-02","conditions":"Tetanus, Hepatitis B, Haemophilus Influenzae Type b","enrollment":800},{"nctId":"NCT00317122","phase":"PHASE3","title":"Assess the Immune Response Following Primary Vaccination With GSK Biologicals' Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ Given at 6,10 & 14 Wks of Age to Infants Who Received Hepatitis B Vaccine at Birth","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-10","conditions":"Diphtheria; Haemophilus Influenzae Type b; Hepatitis B; Tetanus; Whole Cell Pertussis","enrollment":192},{"nctId":"NCT00290303","phase":"PHASE3","title":"Assess if Immune Response of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Given Without or With Hepatitis B Vaccine at Birth is at Least as Good as Tritanrix™-HepB/Hiberix™ Without Hepatitis B Vaccine at Birth, When Given to Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-05","conditions":"Haemophilus Influenzae Type b, Diphtheria, Whole Cell Pertussis","enrollment":996},{"nctId":"NCT00291967","phase":"PHASE2","title":"Assess Immune Response Following Primary Vaccination With Tritanrix™-HepB Vaccine Mixed With 3 Formulations of Hib-MenAC Vaccine to Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-11","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":525}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Tritanrix-HepB/Hib-MenAC","genericName":"Tritanrix-HepB/Hib-MenAC","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"Tritanrix-HepB/Hib-MenAC is a vaccine that protects against diphtheria, tetanus, hepatitis B, and meningococcal and Haemophilus influenzae type b diseases. Used for Protection against diphtheria, tetanus, hepatitis B, and meningococcal and Haemophilus influenzae type b diseases.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}